Healthcare / BiotechnologyTaipei Exchange
$12.80
+0.80 (+6.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-496.8M · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.9%
↓Gross Margin
65.4%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-421716.8%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $185000.0 · net income $-754.4M · FCF $-780.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $185000.00 | $185000.00 | $427000.00 | $16.6M | — |
| Net Income | $-754.4M | $-754.4M | $-496.7M | $-817.3M | $-1.41B |
| EBITDA | $-642.1M | $-642.1M | $-385.8M | $-764.5M | $-1.39B |
| EPS | — | — | -0.87 | -1.44 | -30.79 |
| Gross Margin | 65.4% | 65.4% | 65.1% | 100.0% | — |
| Operating Margin | -523891.9% | -523891.9% | -177493.9% | -2627.5% | — |
| Net Margin | -407784.3% | -407784.3% | -116334.4% | -4925.7% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.04 | -0.02 |
| Current Ratio | 20.29 | 20.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-780.2M | $-780.2M | $-496.8M | $-462.1M | $-380.5M |
| Returns | |||||
| ROE | -13.9% | -13.9% | -7.8% | -12.7% | 47.0% |
| Valuation | |||||
| P/B | 1.38 | 1.38 | 1.57 | 2.86 | — |
| Growth & Yield | |||||
| Revenue Growth | -56.7% | -56.7% | -97.4% | — | — |
| EPS Growth | — | — | 39.6% | 95.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.87 → n/d
Residual
-29.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.